CLS expands the product portfolio with new diffusing fiber for optimal thermal treatment of larger cancer tumors
Clinical Laserthermia Systems (CLS) (publ), has started the development of a new diffusing fiber, and will thereby expand the product portfolio with yet another fiber for treatment of cancer tumors, based on the same unique technology as the company’s existing TRANBERG® |Laser Applicator, none-cooled, diffuser. With the new fiber it will be possible to treat larger tumors and achieve an ablation size of up to about 40 millimeters. Like the existing diffusing fiber from CLS the new product can used for treatment with image guided laser ablation as well as for CLS’s proprietary imILT® treatment.
”Our none-cooled diffusing fiber works very well. To continue to build on the same technology, and offer a new variant of the fiber, strengthens our position as a provider”, said Lars-Erik Eriksson, CEO of CLS. ”The physicians see a need for this type of diffusing fiber, primarily for image guided laser ablation, where this new product will mean shorter treatment time when treating larger tumors”, said Lars-Erik Eriksson.
CLS plans for the new product to be ready for market introduction around mid 2018, provided a clearance for the US market is received from the American FDA. For the European market there is no need for an additional approval, since the new product is covered by the company’s CE approval for existing fiber products.
CLS develops and markets the TRANBERG®|Thermal Therapy System, as well as disposable materials and methods for heat-induced immunotherapy for safe and gentle treatment of cancerous tumors. The Company recently bought the part of the German laser technology company Laser- und Medizin-Technologie GmbH (LMTB), that includes technology and development of CLS diffusor fiber. The production of the fiber is based on unique expertise in micro-structuring of laser fiber, which is the formation of the structure that gives the light its unique diffusion.
This information is such that Clinical Laserthermia Systems AB (publ) is required to publish pursuant to the EE Market Abuse Directive. The contact person arranged for the release of this information on 28 November 2017, at 5:10 PM CET.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: email@example.com
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se